Prediction of fracture risk is increasingly used to guide clinical use of antiosteoporosis drugs. Data from a large primary care prospective study in 10 countries has now been used to generate an empirical composite 5-year fracture risk model based on clinical data (excluding BMD). This model performed better than current widely used models.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bolland, M. J. et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J. Bone Miner. Res. 26, 420–427 (2011).
Aspray, T. J. New horizons in fracture risk assessment. Age Ageing 42, 548–554 (2013).
Nayak, S., Edwards, D. L., Saleh, A. A. & Greenspan, S. L. Performance of risk assessment instruments for predicting osteoporotic fracture risk: a systematic review. Osteoporos. Int. 25, 23–49 (2014).
FitzGerald, G. et al. Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J. Clin. Endocrinol. Metabol. http://dx.doi.org/10.1210/jc.2013-3468.
Hooven, F. H. et al. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos. Int. 20, 1107–1116 (2009).
Harrell, F. E. Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. JAMA 247, 2543–2546 (1982).
Kanis, J. A. et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18, 1033–1046 (2007).
Brennan, S. L. et al. FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporos. Int. 25, 61–69 (2014).
Nguyen, N. D., Frost, S. A., Center, J. R., Eisman, J. A. & Nguyen, T. V. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int. 19, 1431–1444 (2008).
Díez-Pérez, A. et al. Risk factors for treatment failure with antiosteoporosis medication: the Global Longitudinal Study of Osteoporosis in Women (GLOW). J. Bone Miner. Res. 29, 260–267 (2014).
Acknowledgements
We join the authors of the FitzGerald et al. manuscript in dedicating these comments to our friend Steven Boonen.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bouillon, R., Vanderschueren, D. Which model to predict fracture risk?. Nat Rev Endocrinol 10, 194–195 (2014). https://doi.org/10.1038/nrendo.2014.15
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.15
